Unknown PHASE1 INTERVENTIONAL 1-arm NCT05228600

YL-13027 in Patients With Advanced Solid Tumors

A Multi-Center, Open-Label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of YL-13027 in Patients With Advanced Solid Tumors

Sponsor: Shanghai YingLi Pharmaceutical Co. Ltd.

Conditions Solid Tumor

Interventions YL-13027

Updated 5 times since 2022 Last updated: May 16, 2022 Started: May 17, 2022 Primary completion: Dec 30, 2022 Completion: Dec 1, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05228600, this PHASE1 trial focuses on Solid Tumor and remains ongoing. Sponsored by Shanghai YingLi Pharmaceutical Co. Ltd., it has been updated 5 times since 2022, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Jan 2024 — Jul 2024 [monthly]

Unknown Status PHASE1

Status: Recruiting → Unknown Status
Jun 2022 — Jan 2024 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Mar 2022 — Jun 2022 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shanghai YingLi Pharmaceutical Co. Ltd.
Yingli Pharma US, Inc

Data source: Shanghai YingLi Pharmaceutical Co. Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States